[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 24, 1982

Cytomegalovirus vaccine work progressing

JAMA. 1982;248(12):1424-1431. doi:10.1001/jama.1982.03330120004002

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Recent reports, extending earlier findings of a possible cytomegalovirus (CMV)-Kaposi's sarcoma (KS) relationship, also are serving to refocus attention on continuing CMV vaccine studies.

One report comes from a ten-month study of ten homosexual men in San Francisco, aged 22 to 48 years, who had the disseminated form of KS, preceded by CMV infections Cytomegalovirus was recovered from urine, saliva, semen, gastric secretions, or peripheral blood leukocytes of seven of these patients. Anti-CMV IgG antibodies (titers ranging from 128 to more than 4,096) were detected in nine patients (one died before serum was obtained), and anti-CMV IgM antibodies (titers ranging from about 8 to more than 128) in seven (Lancet 1982;2:125-127).

A decade earlier, herpeslike viral particles were reported in five of eight tissue culture lines from African KS (also the disseminated form) biopsy specimens (J Nat Cancer Inst 1972;49:1509-1513). Later in that decade, serum antibody to CMV was detected